Garijo starts as Sanofi CEO with window to ease reliance on Dupixent
The new CEO has at least five years and a large M&A war chest to position Sanofi for life after the loss of exclusivity on its cornerstone immunology product.
Garijo starts as Sanofi CEO with window to ease reliance on Dupixent Read More »
